nach oben

Acta Neuropathologica

Erschienen in:

01.09.2012 | Review

The genetics and neuropathology of amyotrophic lateral sclerosis

verfasst von: Ammar Al-Chalabi, Ashley Jones, Claire Troakes, Andrew King, Safa Al-Sarraj, Leonard H. van den Berg

Erschienen in: Acta Neuropathologica | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons leading to death from respiratory failure within about 3 years of symptom onset. A family history of ALS is obtained in about 5 % but the distinction between familial and apparently sporadic ALS is artificial and genetic factors play a role in all types. For several years, only one gene was known to have a role in ALS pathogenesis, SOD1. In the last few years there has been a rapid advance in our genetic knowledge of the causes of ALS, and the relationship of the genetic subtypes with pathological subtypes and clinical phenotype. Mutations in the gene for TDP-43 protein, TARDBP, highlight this, with pathology mimicking closely that found in other types of ALS, and a phenotypic spectrum that includes frontotemporal dementia. Mutations in the FUS gene, closely related to TDP-43, lead to a similar clinical phenotype but distinct pathology, so that the three pathological groups represented by SOD1, TARDBP, and FUS are distinct. In this review, we explore the genetic architecture of ALS, highlight some of the genes implicated in pathogenesis, and describe their phenotypic range and overlap with other diseases.

Al-Chalabi A, Andersen PM, Nilsson P et al (1999) Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 8:157–164. doi:10.1093/hmg/8.2.157 PubMedCrossRef

Al-Chalabi A, Fang F, Hanby MF et al (2010) An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 81:1324–1326. doi:10.1136/jnnp.2010.207464 PubMedCrossRef

Al-Chalabi A, Lewis CM (2011) Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered 71:281–288. doi:10.1159/000330167 PubMedCrossRef

Al-Saif A, Al-Mohanna F, Bohlega S (2011) A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol 70:913–919. doi:10.1002/ana.22534 PubMedCrossRef

Al-Sarraj S, King A, Troakes C et al (2011) p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol 122:691–702. doi:10.1007/s00401-011-0911-2 PubMedCrossRef

Andersen PM, Nilsson P, Ala-Hurula V et al (1995) Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat Genet 10:61–66. doi:10.1038/ng0595-61 PubMedCrossRef

Andersen PM, Al-Chalabi A (2011) Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 7:603–615. doi:10.1038/nrneurol.2011.150 PubMedCrossRef

Beckman JS, Carson M, Smith CD, Koppenol WH (1993) ALS, SOD and peroxynitrite. Nature 364:584PubMedCrossRef

Bosco DA, Morfini G, Karabacak NM et al (2010) Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 13:1396–1403. http://www.nature.com/neuro/journal/v13/n11/abs/nn.2660.html#supplementary-information

10.

Boxer AL, Mackenzie IR, Boeve BF et al (2009) Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp.2009.204081

11.

Boxer AL, Mackenzie IR, Boeve BF et al (2011) Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatr. doi:10.1136/jnnp.2009.204081 PubMed

12.

Brotherton T, Polak M, Kelly C et al (2011) A novel ALS SOD1 C6S mutation with implications for aggregation related toxicity and genetic counseling. Amyotroph Later Scler Off Publ World Fed Neurol Res Group Motor Neuron Dis 12:215–219. doi:10.3109/17482968.2010.531279

13.

Byrne S, Hardiman O (2010) Familial aggregation in amyotrophic lateral sclerosis. Ann Neurol 67:554. doi:10.1002/ana.21883 PubMedCrossRef

14.

Byrne S, Bede P, Elamin M et al (2011) Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Later Scler Off Publ World Fed Neurol Res Group Motor Neuron Dis 12:157–159. doi:10.3109/17482968.2010.545420

15.

Byrne S, Walsh C, Lynch C et al (2011) Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatr 82:623–627. doi:10.1136/jnnp.2010.224501 PubMedCrossRef

16.

Byrne S, Elamin M, Bede P et al (2012) Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. doi:10.1016/S1474-4422(12)70014-5

17.

Chen Y, Bennett C, Huynh H et al (2004) DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 74:1128–1135PubMedCrossRef

18.

Chen Y, Huang R, Yang Y et al (2011) Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis. Neurobiol Aging 32(1925):e1921–e1925. doi:10.1016/j.neurobiolaging.2011.05.015

19.

Chio A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R (2009) Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 72:725–731. doi:10.1212/01.wnl.0000343008.26874.d1 PubMedCrossRef

20.

Chow CY, Landers JE, Bergren SK et al (2009) Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am J Hum Genet 84:85–88PubMedCrossRef

21.

Corrado L, Carlomagno Y, Falasco L et al (2011) A novel peripherin gene (PRPH) mutation identified in one sporadic amyotrophic lateral sclerosis patient. Neurobiol Aging 32:552.e551–552.e556. doi:10.1016/j.neurobiolaging.2010.02.011

22.

Couthouis J, Hart MP, Shorter J et al (2011) A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci USA 108:20881–20890. doi:10.1073/pnas.1109434108 PubMedCrossRef

23.

Couthouis J, Hart MP, Erion R et al (2012) Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet 21:2899–2911. doi:10.1093/hmg/dds116 PubMedCrossRef

24.

Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS (1997) Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J Neurochem 69:1936–1944. doi:10.1046/j.1471-4159.1997.69051936.x PubMedCrossRef

25.

Daoud H, Belzil V, Martins S et al (2011) Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch Neurol 68:739–742. doi:10.1001/archneurol.2011.111 PubMedCrossRef

26.

DeJesus-Hernandez M, Desaro P, Johnston A et al (2011) Novel p.Ile151Val mutation in VCP in a patient of African American descent with sporadic ALS. Neurology 77:1102–1103. doi:10.1212/WNL.0b013e31822e563c PubMedCrossRef

27.

DeJesus-Hernandez M, Mackenzie IR, Boeve BF et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245–256. doi:10.1016/j.neuron.2011.09.011 PubMedCrossRef

28.

Deng HX, Zhai H, Bigio EH et al (2010) FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol 67:739–748. doi:10.1002/ana.22051 PubMedCrossRef

29.

Deng HX, Chen W, Hong ST et al (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477:211–215. doi:10.1038/nature10353 PubMedCrossRef

30.

Devon RS, Helm JR, Rouleau GA et al (2003) The first nonsense mutation in alsin results in a homogeneous phenotype of infantile-onset ascending spastic paralysis with bulbar involvement in two siblings. Clin Genet 64:210–215PubMedCrossRef

31.

Diekstra FP, van Vught PW, van Rheenen W et al (2012) UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging 33(630):e633–e638. doi:10.1016/j.neurobiolaging.2011.10.029

32.

Dormann D, Rodde R, Edbauer D et al (2010) ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J 29:2841–2857. http://www.nature.com/emboj/journal/v29/n16/suppinfo/emboj2010143a_S1.html

33.

Elden AC, Kim H-J, Hart MP et al (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466:1069–1075. http://www.nature.com/nature/journal/v466/n7310/abs/nature09320.html#supplementary-information

34.

Eymard-Pierre E, Lesca G, Dollet S et al (2002) Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. Am J Hum Genet 71:518–527. doi:10.1086/342359 PubMedCrossRef

35.

Fecto F, Siddique T (2012) UBQLN2/P62 cellular recycling pathways in amyotrophic lateral sclerosis and frontotemporal dementia. Muscle Nerve 45:157–162. doi:10.1002/mus.23278 PubMedCrossRef

36.

Figlewicz DA, Krizus A, Martinoli MG et al (1994) Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 3:1757–1761PubMedCrossRef

37.

Garcia ML, Singleton AB, Hernandez D et al (2006) Mutations in neurofilament genes are not a significant primary cause of non-SOD1-mediated amyotrophic lateral sclerosis. Neurobiol Dis 21:102–109. doi:10.1016/j.nbd.2005.06.016 PubMedCrossRef

38.

Gijselinck I, Van Langenhove T, van der Zee J et al (2012) A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 11:54–65. doi:10.1016/S1474-4422(11)70261-7 PubMedCrossRef

39.

Gispert S, Kurz A, Waibel S et al (2012) The modulation of amyotrophic lateral sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis 45:356–361. doi:10.1016/j.nbd.2011.08.021 PubMedCrossRef

40.

Gitcho MA, Baloh RH, Chakraverty S et al (2008) TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol 63:535–538. doi:10.1002/ana.21344 PubMedCrossRef

41.

Goodall EF, Greenway MJ, van Marion I, Carroll CB, Hardiman O, Morrison KE (2005) Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology 65:934–937. doi:10.1212/01.wnl.0000176032.94434.d4 PubMedCrossRef

42.

Greenway MJ, Andersen PM, Russ C et al (2006) ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis. Nat Genet 38:411–413. doi:10.1038/ng1742 PubMedCrossRef

43.

Gros-Louis F, Larivière R, Gowing G et al (2004) A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. J Biol Chem 279:45951–45956. doi:10.1074/jbc.M408139200 PubMedCrossRef

44.

Gunnarsson LG, Dahlbom K, Strandman E (1991) Motor neuron disease and dementia reported among 13 members of a single family. Acta Neurol Scand 84:429–433PubMedCrossRef

45.

Gurney M, Pu H, Chiu A et al (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264:1772–1775. doi:10.1126/science.8209258 PubMedCrossRef

46.

Hadano S, Hand C, Osuga H et al (2001) A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 29:166–173PubMedCrossRef

47.

Hanby MF, Scott KM, Scotton W et al (2011) The risk to relatives of patients with sporadic amyotrophic lateral sclerosis. Brain J Neurol 134:3454–3457. doi:10.1093/brain/awr248 CrossRef

48.

Hayward C, Colville S, Swingler RJ, Brock DJ (1999) Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis. Neurology 52:1899–1901PubMedCrossRef

49.

Higgins CMJ, Jung C, Ding H, Xu Z (2002) Mutant Cu, Zn Superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J Neurosci 22:RC215

50.

Hortobagyi T, Troakes C, Nishimura AL et al (2011) Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders. Acta Neuropathol 121:519–527. doi:10.1007/s00401-011-0813-3 PubMedCrossRef

51.

Huisman MH, de Jong SW, Verwijs MC et al (2011) Family history of neurodegenerative and vascular diseases in ALS: a population-based study. Neurology 77:1363–1369. doi:10.1212/WNL.0b013e318231530b PubMedCrossRef

52.

Johnson JO, Mandrioli J, Benatar M et al (2010) Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68:857–864PubMedCrossRef

53.

Johnston CA, Stanton BR, Turner MR et al (2006) Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol 253:1642–1643. doi:10.1007/s00415-006-0195-y PubMedCrossRef

54.

Julien JP, Côté F, Collard JF (1995) Mice overexpressing the human neurofilament heavy gene as a model of ALS. Neurobiol Aging 16:487–490. doi:10.1016/0197-4580(94)00169-2 PubMedCrossRef

55.

Kabashi E, Valdmanis PN, Dion P et al (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40:572–574. doi:http://www.nature.com/ng/journal/v40/n5/suppinfo/ng.132_S1.html

56.

King A, Maekawa S, Bodi I, Troakes C, Al-Sarraj S (2011) Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP-43 proteinopathies but are only rarely additionally immunopositive for phosphorylation-dependent TDP-43. Neuropathol Off J Jpn Soc Neuropathol 31:239–249. doi:10.1111/j.1440-1789.2010.01171.x CrossRef

57.

Koppers M, van Blitterswijk MM, Vlam L et al (2011) VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2011.10.006

58.

Kwiatkowski TJ Jr, Bosco DA, LeClerc AL et al (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205–1208. doi:10.1126/science.1166066 PubMedCrossRef

59.

Laaksovirta H, Peuralinna T, Schymick JC et al (2010) Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol 9:978–985. doi:10.1016/S1474-4422(10)70184-8 PubMedCrossRef

60.

Lagier-Tourenne C, Cleveland DW (2009) Rethinking ALS: the FUS about TDP-43. Cell 136:1001–1004. doi:10.1016/j.cell.2009.03.006 PubMedCrossRef

61.

Lambrechts D, Storkebaum E, Morimoto M et al (2003) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34:383–394. doi:10.1038/ng1211ng1211 PubMedCrossRef

62.

Landers JE, Leclerc AL, Shi L et al (2008) New VAPB deletion variant and exclusion of VAPB mutations in familial ALS. Neurology 70:1179–1185. doi:10.1212/01.wnl.0000289760.85237.4e PubMedCrossRef

63.

Landers JE, Melki J, Meininger V et al (2009) Reduced expression of the kinesin-associated protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 106:9004–9009. doi:10.1073/pnas.0812937106 PubMedCrossRef

64.

Lansbury PT, Lashuel HA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443:774–779PubMedCrossRef

65.

Leigh P, Whitwell H, Garofalo O et al (1991) Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain J Neurol 114:775–788CrossRef

66.

Leigh PN, Dodson A, Swash M, Brion JP, Anderton BH (1989) Cytoskeletal abnormalities in motor neuron disease. An immunocytochemical study. Brain J Neurol 112(Pt 2):521–535

67.

Lesca G, Eymard-Pierre E, Santorelli FM et al (2003) Infantile ascending hereditary spastic paralysis (IAHSP): clinical features in 11 families. Neurology 60:674–682PubMedCrossRef

68.

Leung CL, He CZ, Kaufmann P et al (2004) A pathogenic peripherin gene mutation in a patient with amyotrophic lateral sclerosis. Brain Pathol 14:290–296. doi:10.1111/j.1750-3639.2004.tb00066.x PubMedCrossRef

69.

Ligon LA, LaMonte BH, Wallace KE, Weber N, Kalb RG, Holzbaur ELFCA (2005) Mutant superoxide dismutase disrupts cytoplasmic dynein in motor neurons. NeuroReport 16:533–536PubMedCrossRef

70.

Lill CM, Abel O, Bertram L, Al-Chalabi A (2011) Keeping up with genetic discoveries in amyotrophic lateral sclerosis: the ALSoD and ALSGene databases. Amyotroph Later Scler Off Publ World Feder Neurol Res Group Motor Neuron Dis 12:238–249. doi:10.3109/17482968.2011.584629

71.

Mackenzie I, Bigio E, Ince P et al (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61:427–434PubMedCrossRef

72.

Mackenzie IR, Rademakers R, Neumann M (2010) TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 9:995–1007. doi:10.1016/S1474-4422(10)70195-2 PubMedCrossRef

73.

Martinaud O, Laquerrière A, Guyant-Maréchal L et al (2005) Frontotemporal dementia, motor neuron disease and tauopathy: clinical and neuropathological study in a family. Acta Neuropathol 110:84–92. doi:10.1007/s00401-005-1028-2 PubMedCrossRef

74.

Maruyama H, Morino H, Ito H et al (2010) Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465:223–226. http://www.nature.com/nature/journal/v465/n7295/suppinfo/nature08971_S1.html

75.

Mitchell J, Paul P, Chen H-J et al (2010) Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Nat Acad Sci USA 107:7556–7561. doi:10.1073/pnas.0914128107 PubMedCrossRef

76.

Morita M, Al-Chalabi A, Andersen PM et al (2006) A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 66:839–844. doi:10.1212/01.wnl.0000200048.53766.b4 PubMedCrossRef

77.

Murray ME, DeJesus-Hernandez M, Rutherford NJ et al (2011) Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 122:673–690. doi:10.1007/s00401-011-0907-y PubMedCrossRef

78.

Nagai M, Re DB, Nagata T et al (2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10:615–622. http://www.nature.com/neuro/journal/v10/n5/suppinfo/nn1876_S1.html

79.

Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133. doi:10.1126/science.1134108 PubMedCrossRef

80.

Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IRA (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain J Neurol 132:2922–2931. doi:10.1093/brain/awp214 CrossRef

81.

Neumann M, Bentmann E, Dormann D et al (2011) FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain J Neurol 134:2595–2609. doi:10.1093/brain/awr201 CrossRef

82.

Nishimura AL, Mitne-Neto M, Silva HC et al (2004) A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 75:822–831. doi:10.1086/425287S0002-9297(07)63787-2 PubMedCrossRef

83.

Nishimura AL, Al-Chalabi A, Zatz M (2005) A common founder for amyotrophic lateral sclerosis type 8 (ALS8) in the Brazilian population. Hum Genet 118:499–500. doi:10.1007/s00439-005-0031-y PubMedCrossRef

84.

Niwa J-I, Yamada S-I, Ishigaki S et al (2007) Disulfide bond mediates aggregation, toxicity, and ubiquitylation of familial amyotrophic lateral sclerosis-linked mutant SOD1. J Biol Chem 282:28087–28095. doi:10.1074/jbc.M704465200 PubMedCrossRef

85.

Orlacchio A, Babalini C, Borreca A et al (2010) SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain J Neurol 133:591–598. doi:10.1093/brain/awp325 CrossRef

86.

Orsetti V, Pegoraro E, Cima V et al (2011) Genetic variation in KIFAP3 is associated with an upper motor neuron-predominant phenotype in amyotrophic lateral sclerosis. Neurodegener Dis 8:491–495. doi:10.1159/000327755 PubMedCrossRef

87.

Osawa T, Mizuno Y, Fujita Y, Takatama M, Nakazato Y, Okamoto K (2011) Optineurin in neurodegenerative diseases. Neuropathol Off J Jpn Soc Neuropathol 31:569–574. doi:10.1111/j.1440-1789.2011.01199.x CrossRef

88.

Page T, Gitcho M, Mosaheb S et al (2011) FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy. J Mol Neurosci 45:409–421. doi:10.1007/s12031-011-9549-8 PubMedCrossRef

89.

Parkinson N, Ince PG, Smith MO et al (2006) ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 67:1074–1077. doi:10.1212/01.wnl.0000231510.89311.8b PubMedCrossRef

90.

Pasinelli P, Brown RH (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7:710–723. http://www.nature.com/nrn/journal/v7/n9/suppinfo/nrn1971_S1.html

91.

Pearson JP, Williams NM, Majounie E et al (2011) Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosome 9p. J Neurol 258:647–655. doi:10.1007/s00415-010-5815-x PubMedCrossRef

92.

Praline J, Blasco H, Vourc’h P et al (2012) Study of the HFE gene common polymorphisms in French patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci 317:58–61. doi:10.1016/j.jns.2012.02.029 PubMedCrossRef

93.

Puls I, Jonnakuty C, LaMonte B et al (2003) Mutant dynactin in motor neuron disease. Nat Genet 33:455–456PubMedCrossRef

94.

Renton AE, Majounie E, Waite A et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257–268. doi:10.1016/j.neuron.2011.09.010 PubMedCrossRef

95.

Rooke K, Figlewicz DA, Han FY, Rouleau GA (1996) Analysis of the KSP repeat of the neurofilament heavy subunit in familiar amyotrophic lateral sclerosis. Neurology 46:789–790PubMedCrossRef

96.

Rosen DR, Siddique T, Patterson D et al (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59–62. doi:10.1038/362059a0 PubMedCrossRef

97.

Ross OA, Rutherford NJ, Baker M et al (2011) Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet 20:3207–3212. doi:10.1093/hmg/ddr227 PubMedCrossRef

98.

Rouleau GA, Clark AW, Rooke K et al (1996) SOD1 mutation is assosiated with accumulation of neurofilaments in amyotrophic lateral scelaries. Ann Neurol 39:128–131. doi:10.1002/ana.410390119 PubMedCrossRef

99.

Shatunov A, Mok K, Newhouse S et al (2010) Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol 9:986–994. doi:10.1016/S1474-4422(10)70197-6 PubMedCrossRef

100.

Shibata N, Hirano A, Kobayashi M et al (1996) Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement. J Neuropathol Exp Neurol 55:481–490PubMedCrossRef

101.

Simpson CL, Lemmens R, Miskiewicz K et al (2009) Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum Mol Genet 18:472–481. doi:10.1093/hmg/ddn375 PubMedCrossRef

102.

Spreux-Varoquaux O, Gilbert B, Lucette L et al (2002) Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 193:73–78PubMedCrossRef

103.

Sreedharan J, Blair IP, Tripathi VB et al (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319:1668–1672. doi:10.1126/science.1154584 PubMedCrossRef

104.

Strong MJ, Yang W, Strong WL, Leystra-Lantz C, Jaffe H, Pant HC (2006) Tau protein hyperphosphorylation in sporadic ALS with cognitive impairment. Neurology 66:1770–1771. doi:10.1212/01.wnl.0000218161.15834.db PubMedCrossRef

105.

Sutedja NA, Sinke RJ, Van Vught PW et al (2007) The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. Arch Neurol 64:63–67. doi:10.1001/archneur.64.1.63 PubMedCrossRef

106.

Tan CF, Eguchi H, Tagawa A et al (2007) TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol 113:535–542. doi:10.1007/s00401-007-0206-9 PubMedCrossRef

107.

Ticozzi N, Vance C, LeClerc AL et al (2011) Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. Am J Med Genet Part B Neuropsychiat Genet 156:285–290. doi:10.1002/ajmg.b.31158 CrossRef

108.

Tiloca C, Ratti A, Pensato V et al (2012) Mutational analysis of VCP gene in familial amyotrophic lateral sclerosis. Neurobiol Aging 33(630):e631–e632. doi:10.1016/j.neurobiolaging.2011.10.025

109.

Tomkins J, Usher P, Slade JY et al (1998) Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). NeuroReport 9:3967–3970PubMedCrossRef

110.

Traynor BJ, Nalls M, Lai SL et al (2010) Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients. Proc Natl Acad Sci USA 107:12335–12338. doi:10.1073/pnas.0914079107 PubMedCrossRef

111.

Troakes C, Maekawa S, Wijesekera L et al (2011) An MND/ALS phenotype associated with C9orf72 repeat expansion: Abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline. Neuropathol Offl J Jpn Soc Neuropathol. doi:10.1111/j.1440-1789.2011.01286.x

112.

Valdmanis PNB, Rouleau GAMDP (2008) Genetics of familial amyotrophic lateral sclerosis. Neurology 70:144–152PubMedCrossRef

113.

Van Damme P, Veldink JH, van Blitterswijk M et al (2011) Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 76:2066–2072. doi:10.1212/WNL.0b013e31821f445b PubMedCrossRef

114.

Van Deerlin VM, Leverenz JB, Bekris LM et al (2008) TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol 7:409–416. doi:10.1016/s1474-4422(08)70071-1 PubMedCrossRef

115.

Van Deerlin VM, Sleiman PM, Martinez-Lage M et al (2010) Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 42:234–239. doi:10.1038/ng.536 PubMedCrossRef

116.

van Es MA, Diekstra FP, Veldink JH et al (2009) A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurology 72:287–288. doi:10.1212/01.wnl.0000339487.84908.00 PubMedCrossRef

117.

van Es MA, Veldink JH, Saris CG et al (2009) Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 41:1083–1087. doi:10.1038/ng.442 PubMedCrossRef

118.

van Es MA, Schelhaas HJ, van Vught PW et al (2011) Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol 70:964–973. doi:10.1002/ana.22611 PubMedCrossRef

119.

Van Langenhove T, van der Zee J, Engelborghs S et al (2011) Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2011.09.025

120.

Van Swieten J, Spillantini MG (2007) Hereditary frontotemporal dementia caused by Tau gene mutations. Brain Pathol 17:63–73. doi:10.1111/j.1750-3639.2007.00052.x PubMedCrossRef

121.

Vance C, Al-Chalabi A, Ruddy D et al (2006) Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain J Neurol 129:868–876. doi:10.1093/brain/awl030 CrossRef

122.

Vance C, Rogelj B, Hortobagyi T et al (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323:1208–1211. doi:10.1126/science.1165942 PubMedCrossRef

123.

Wang XS, Lee S, Simmons Z et al (2004) Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci 227:27–33. doi:10.1016/j.jns.2004.08.003 PubMedCrossRef

124.

Wicks P, Abrahams S, Papps B et al (2009) SOD1 and cognitive dysfunction in familial amyotrophic lateral sclerosis. J Neurol 256:234–241. doi:10.1007/s00415-009-0078-0 PubMedCrossRef

125.

Wiedau-Pazos M, Goto JJ, Rabizadeh S et al (1996) Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 271:515–518PubMedCrossRef

126.

Williams KL, Solski JA, Nicholson GA, Blair IP (2011) Mutation analysis of VCP in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2011.11.022

127.

Williams KL, Warraich ST, Yang S et al (2012) UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2012.05.008

128.

Yang W, Ang LC, Strong MJ (2005) Tau protein aggregation in the frontal and entorhinal cortices as a function of aging. Dev Brain Res 156:127–138. doi:10.1016/j.devbrainres.2005.02.004 CrossRef

129.

Yang Y, Hentati A, Deng HX et al (2001) The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 29:160–165. doi:10.1038/ng1001-160 PubMedCrossRef

130.

Yen AA, Simpson EP, Henkel JS, Beers DR, Appel SH (2004) HFE mutations are not strongly associated with sporadic ALS. Neurology 62:1611–1612PubMedCrossRef

131.

Yokoseki A, Shiga A, Tan CF et al (2008) TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol 63:538–542. doi:10.1002/ana.21392 PubMedCrossRef

132.

Yu Z, Zhu Y, Chen-Plotkin AS et al (2011) PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. PLoS One 6:e17951. doi:10.1371/journal.pone.0017951 PubMedCrossRef

133.

Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM (2008) Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. J Neurol Sci 273:67–69. doi:10.1016/j.jns.2008.06.025 PubMedCrossRef

Titel: The genetics and neuropathology of amyotrophic lateral sclerosis
verfasst von: Ammar Al-Chalabi
Ashley Jones
Claire Troakes
Andrew King
Safa Al-Sarraj
Leonard H. van den Berg
Publikationsdatum: 01.09.2012
Verlag: Springer-Verlag
Erschienen in: Acta Neuropathologica / Ausgabe 3/2012
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-012-1022-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

The genetics and neuropathology of frontotemporal lobar degeneration

The genetics and neuropathology of Alzheimer’s disease

Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain

Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects

Fingolimod attenuates ceramide-induced blood–brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes